Understanding how PRMT5 helps prevent DNA deletions in cancer cells
Official title: The role of PRMT5 in preventing intra-chromosomal deletions in cancer cells
Funded at Ohio State University · NIH-10890183 · Data updated 2026-11-12
This study is looking at how a protein called PRMT5 helps keep DNA safe during cell division, especially in cancer cells, and it hopes to find new ways to treat cancer by understanding how PRMT5 works with other proteins to fix DNA damage.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | August 1, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $78,750 |
| NIH project number | 5R03CA276967-02 |
| Project ID | NIH-10890183 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with cancers associated with BRCA1/2 mutations or other DNA repair deficiencies.
✕Less likely to help
Patients with cancers unrelated to DNA repair mechanisms or those without genetic predispositions may not benefit from this research.
What this research studies
This research investigates the role of the PRMT5 enzyme in maintaining the integrity of DNA during cell division, particularly in cancer cells. It focuses on how PRMT5 influences the repair of DNA double strand breaks, which can lead to harmful genetic deletions if not properly managed. By utilizing advanced assays and artificial intelligence algorithms, the study aims to uncover the mechanisms by which PRMT5 operates and its interactions with other key proteins involved in DNA repair. This could provide insights into potential therapeutic targets for cancer treatment.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing genetic mutations in cancer, potentially improving treatment outcomes.
How similar studies have gone: Previous research has shown promising results in understanding DNA repair mechanisms, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Petreaca, Ruben Ciprian — Ohio State University
- Study coordinator: Petreaca, Ruben Ciprian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.